ITALIAN NOBEL PRIZE BRIBE CLAIM DENIED

7 March 1994

The Nobel Prize committee has dismissed as "absolutely untrue" a claim by former Italian health official Duilio Poggiolini that Rita Levi Montalcini won the Nobel Prize for Medicine jointly in 1986 following a bribe paid by pharmaceutical company Fidia (Marketletter february 21). Margareta Petrini, secretary to the Nobel Assembly at Stockholm's Karolinska Institute, said the claim was "so unreal there is no possibility of it happening."

Under questioning by Italian judges, Prof Poggiolini, ex-director of the pharmaceutical service at Italy's Ministry of Health, alleged that Fidia paid the Nobel Committee to ensure that Prof Levi Montalcini won the $290,000 prize, which she shared with Stanley Cohen of the USA for research into tissue regeneration and growth factors. Prof Poggiolini said that Fidia paid $8 million to the prize committee, but that a part of that sum was earmarked to pay for Prof Levi Montalcini's research. He added that he had found out about the payment from Francesco della Valle, the former head of Fidia in Italy.

Prof Levi Montalcini has called the incident a "disgrace" for the entire scientific community. She has received expressions of solidarity and support from the Italian scientific community and from the country's president, Oscar luigi Scalfaro.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight